Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
May 26 2016 - 7:00AM
Business Wire
Alkermes plc (NASDAQ: ALKS) today announced the appointment of
Nancy L. Snyderman, M.D., to the company’s Board of Directors. Dr.
Snyderman most recently served as Chief Medical Editor at NBC News,
and has more than three decades of experience as a leading voice in
healthcare and medicine. Dr. Snyderman is a board certified
Otolaryngologist-Head and Neck Surgeon and Fellow in the American
College of Surgeons.
“We are delighted to welcome Nancy to our Board of Directors.
She has exceptional insights from her range of experiences as a
surgeon, medical journalist and advisor to major organizations, and
will bring a unique and valuable perspective to Alkermes,” said
Richard Pops, Chief Executive Officer of Alkermes. “Nancy has a
deep understanding of the value of medical innovation as well as
the barriers that must be overcome in order to bring it to
physicians, patients and communities. She will be a key strategic
advisor as our products and pipeline are beginning to have a
greater impact in the evolving healthcare ecosystem.”
Dr. Snyderman currently serves on the Board of Directors of GE’s
Healthymagination and on the Global Health Advisory Council for
Anheuser-Busch InBev. She is a board member of the Institute for
Healthcare Improvement in Cambridge, Mass., the Albright Institute
at Wellesley College, The Eye and Ear Foundation at the University
of Pittsburgh Medical Center, and the National Meningitis
Foundation. She is a Consulting Professor in the School of Global
Health at Stanford University and a Consulting Professor of Medical
Communication in the School of Public Health at the University of
Nebraska Medical Center. Dr. Snyderman co-founded the Stanford
University-NBC News Global Media Fellowship.
In addition, Dr. Snyderman has 28 years of experience as a
medical journalist at NBC News and ABC News. She has reported on a
wide-range of medical topics from global locations and has
explained complex scientific breakthroughs to the public through
television, radio, print and online media. She has received
distinguished honors for her reporting, including Emmy Awards, an
Edward R. Murrow Award, a Columbia University DuPont Award and a
Gracie Award. Prior to her work in journalism, Dr. Snyderman worked
at Johnson & Johnson as Vice President of Corporate
Communications.
Beginning in 1983, Dr. Snyderman held medical roles in
Otolaryngology-Head and Neck Surgery at the University of Arkansas
Hospital and the University of California at San Francisco Medical
Center. Dr. Snyderman attended the University of Nebraska Medical
School and completed residencies in Pediatrics and
Otolaryngology-Head and Neck Surgery at the University of
Pittsburgh. She is an author on more than 60 peer-reviewed research
articles and publications in the field of otolaryngology. Dr.
Snyderman’s more recent publications include five books in the
general press, including a New York Times bestseller.
“I am delighted to join Alkermes’ Board of Directors at a time
when the company is clearly beginning to have an important impact
on critical diseases of our time, including addiction and
schizophrenia,” said Dr. Snyderman. “I look forward
to applying the insights that I have acquired through my
years of experience working within many realms
of the medical community, and contributing to the achievement
of Alkermes’ mission to advance innovative medicines and help
patients and their families.”
About AlkermesAlkermes
plc is a fully integrated, global biopharmaceutical company
developing innovative medicines for the treatment of central
nervous system (CNS) diseases. The company has a diversified
commercial product portfolio and a substantial clinical pipeline of
product candidates for chronic diseases that include schizophrenia,
depression, addiction and multiple sclerosis. Headquartered in
Dublin, Ireland, Alkermes plc has an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in Athlone,
Ireland; and a manufacturing facility in Wilmington, Ohio. For more
information, please visit Alkermes’ website
at www.alkermes.com.
Note Regarding Forward-Looking
StatementsCertain statements set forth in this press
release constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended, including, but not limited to, statements concerning the
therapeutic value and commercial potential of our product
candidates and proprietary products. The company cautions that
forward-looking statements are inherently uncertain. Although the
company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and they are necessarily subject to a high degree of
uncertainty and risk. Actual performance and results may differ
materially from those expressed or implied in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include those risks described in the Alkermes plc
Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2015,
and in other subsequent filings made by the company with the U.S.
Securities and Exchange Commission (SEC), which are available on
the SEC’s website at www.sec.gov. The information contained in this
press release is provided by the company as of the date hereof,
and, except as required by law, the company disclaims any intention
or responsibility for updating or revising any forward-looking
information contained in this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160526005222/en/
AlkermesFor Investors:Sandra Coombs, +1 781-609-6377orFor
Media:Jennifer Snyder, +1 781-609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024